Roivant Sciences Ltd
ROIV11.270USD
-0.040-0.35%
交易中 （美東）報價延遲15分鐘
7.84B總市值
虧損本益比TTM
關於 Roivant Sciences Ltd 公司
Roivant Sciences Ltd. 是一家生物製藥公司，致力於通過加速重要藥物的開發和商業化來改善患者的生活。該公司的產品線包括免疫學、腫瘤學、血液學和皮膚病學等各個治療領域的候選產品。其產品線包括 IMVT-1402 和 batoclimab，它們是針對 FcRn 的完全人源單克隆抗體，正在開發用於多種 IgG 介導的自身免疫適應症；brepocitinib，一種 TYK2 和 JAK1 的小分子抑制劑，正在開發用於治療皮肌炎和非感染性葡萄膜炎；mosliciguat，一種吸入性可溶性 sGC 激活劑，正在開發用於治療與間質性肺病相關的肺動脈高壓，此外還有其他臨牀階段的分子；和 namilumab 是一種完全人源單克隆抗體，針對粒細胞-巨噬細胞集落刺激因子，一種與結節病等炎症性疾病有關的炎症細胞因子。
公司簡介
公司代碼ROIV
公司名稱Roivant Sciences Ltd
上市日期Dec 03, 2020
CEODr. Eric Venker, M.D.
員工數量750
證券類型Ordinary Share
年結日Dec 03
公司地址11-12 St. James's Square
城市LONDON
上市交易所NASDAQ Global Select Consolidated
國家United Kingdom
郵編SW1Y4LB
電話
網址http://roivant.com/
公司代碼ROIV
上市日期Dec 03, 2020
CEODr. Eric Venker, M.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.92M
+52.26%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.51M
-82.14%
Mr. Richard Pulik
Mr. Richard Pulik
Chief Financial Officer
Chief Financial Officer
195.73K
-22.03%
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
112.25K
--
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
86.09K
-0.88%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
80.26K
+3.05%
Mr. Matthew Gline
Mr. Matthew Gline
Chief Executive Officer, Director
Chief Executive Officer, Director
78.94K
-99.54%
Ms. Melissa B. Epperly
Ms. Melissa B. Epperly
Independent Director
Independent Director
26.58K
+12.86%
Mr. Daniel Gold
Mr. Daniel Gold
Independent Director
Independent Director
--
--
Dr. Mayukh Sukhatme, M.D.
Dr. Mayukh Sukhatme, M.D.
President, Chief Investment Officer, Director
President, Chief Investment Officer, Director
--
-100.00%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.92M
+52.26%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.51M
-82.14%
Mr. Richard Pulik
Mr. Richard Pulik
Chief Financial Officer
Chief Financial Officer
195.73K
-22.03%
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
112.25K
--
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
86.09K
-0.88%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
80.26K
+3.05%
收入明細
FY2025Q1
業務USD
名稱
營收
佔比
VTAMA
55.13M
0.00%
地區USD
名稱
營收
佔比
United States
55.13M
0.00%
業務
地區
業務USD
名稱
營收
佔比
VTAMA
55.13M
0.00%
股東統計
更新時間: 7月31日 週四
更新時間: 7月31日 週四
持股股東
股東類型
持股股東
持股股東
佔比
Dexcel Pharma Technologies, Ltd.
15.07%
QVT Financial LP
9.64%
SB Investment Advisers (UK) Limited
9.06%
Fidelity Management & Research Company LLC
7.57%
Ramaswamy (Vivek)
7.43%
Other
51.23%
持股股東
持股股東
佔比
Dexcel Pharma Technologies, Ltd.
15.07%
QVT Financial LP
9.64%
SB Investment Advisers (UK) Limited
9.06%
Fidelity Management & Research Company LLC
7.57%
Ramaswamy (Vivek)
7.43%
Other
51.23%
股東類型
持股股東
佔比
Investment Advisor
27.91%
Hedge Fund
21.65%
Investment Advisor/Hedge Fund
20.04%
Corporation
15.07%
Private Equity
10.93%
Individual Investor
9.31%
Research Firm
1.18%
Sovereign Wealth Fund
0.69%
Pension Fund
0.52%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
668
774.44M
112.09%
-150.07M
2025Q1
676
776.88M
113.63%
-136.03M
2024Q4
645
780.70M
109.07%
-147.12M
2024Q3
601
789.51M
107.30%
-83.47M
2024Q2
564
721.13M
95.89%
-110.95M
2024Q1
518
776.24M
96.43%
-47.46M
2023Q4
449
787.20M
97.95%
-13.44M
2023Q3
421
794.31M
100.15%
+12.61M
2023Q2
394
761.99M
100.91%
+10.72M
2023Q1
340
722.66M
96.55%
+15.87M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Dexcel Pharma Technologies, Ltd.
102.85M
15.13%
--
--
Jul 01, 2024
QVT Financial LP
65.79M
9.68%
--
--
Mar 31, 2025
SB Investment Advisers (UK) Limited
61.85M
9.1%
-204.82K
-0.33%
Mar 31, 2025
Fidelity Management & Research Company LLC
51.67M
7.6%
+2.36M
+4.80%
Mar 31, 2025
Ramaswamy (Vivek)
50.64M
7.45%
-1.89M
-3.60%
Jun 20, 2025
Viking Global Investors LP
46.01M
6.77%
-1.80M
-3.76%
Mar 31, 2025
The Vanguard Group, Inc.
40.68M
5.98%
-3.32M
-7.54%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
37.01M
5.44%
-465.70K
-1.24%
Mar 31, 2025
Morgan Stanley Investment Management Inc. (US)
31.00M
4.56%
+731.14K
+2.42%
Mar 31, 2025
State Street Global Advisors (US)
18.86M
2.77%
-1.94M
-9.33%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Invesco S&P MidCap 400 Pure Growth ETF
2.15%
Virtus LifeSci Biotech Products ETF
1.89%
SPDR S&P Biotech ETF
1.69%
WisdomTree US Value Fund
0.97%
Direxion Daily S&P Biotech Bull 3X Shares
0.96%
Invesco Nasdaq Biotechnology ETF
0.85%
ProShares Ultra Nasdaq Biotechnology
0.85%
WisdomTree BioRevolution Fund
0.8%
WisdomTree US MidCap Fund
0.72%
Goldman Sachs Future Health Care Equity ETF
0.72%
查看更多
Invesco S&P MidCap 400 Pure Growth ETF
佔比2.15%
Virtus LifeSci Biotech Products ETF
佔比1.89%
SPDR S&P Biotech ETF
佔比1.69%
WisdomTree US Value Fund
佔比0.97%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.96%
Invesco Nasdaq Biotechnology ETF
佔比0.85%
ProShares Ultra Nasdaq Biotechnology
佔比0.85%
WisdomTree BioRevolution Fund
佔比0.8%
WisdomTree US MidCap Fund
佔比0.72%
Goldman Sachs Future Health Care Equity ETF
佔比0.72%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
